AbbVie's HOLKIRA™ PAK Now Reimbursed in Ontario
Common Drug Review grants positive recommendation for HOLKIRA PAK Ontario is the second province in Canada to reimburse HOLKIRA PAK In Phase 3 clinical trials, HOLKIRA PAK (with or without ribavirin)...
View ArticleOngoing Real World Study Reports High Sustained Viral Response Rates with...
(Source: AbbVie Inc) - Interim results from the independent AMBER study demonstrated 98 percent (n=39/40) SVR(12) rate in patients who completed a 12- or 24-week treatment regimen and 12 weeks...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
- 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ --...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
(Source: AbbVie Inc) - 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill. , June 24,...
View ArticleAbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with...
NORTH CHICAGO, Ill., Feb. 27, 2017 /PRNewswire/ -- AbbVie ABBV, +0.24% a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the...
View ArticleLupin Bolsters US Brands Portfolio with Methergine® Oral Tablets
MUMBAI, India and BALTIMORE, April 28, 2016 /PRNewswire/ -- The only FDA-approved oral uterotonic for the management of PPH, comes to market with a significant investment in professional medical...
View ArticleMerck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, applauds the U.S. Department of Veterans Affairs (VA) for broadening...
View ArticleMerck to Present New Findings from Chronic Hepatitis C Clinical Development...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the...
View ArticleMerck Announces Results From Phase 3 Studies of ZEPATIER(TM) (Elbasvir and...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER™ (elbasvir and grazoprevir)...
View ArticleMerck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3...
View ArticleAbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with...
- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal...
View ArticleMerck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE...
View ArticleMerck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleBristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for...
(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
(Source: Johnson & Johnson) Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression TITUSVILLE, N.J., September 8, 2015...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
TITUSVILLE, N.J., Sept. 8, 2015 /PRNewswire/ -- Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of people living with HIV said they give advice or tell...
View ArticleU.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV...
(Source: Johnson & Johnson) Data shows PREZISTA is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy...
View Article